


**Unleashing the Power of Cell-Free:**

**PUREfres<sup>®</sup> for Protein Engineering and Discovery**




**Takashi (Ebi) Ebihara, Ph.D.**  
**COO**  
**GeneFrontier Corporation**



**Biologics US 2025**  
**2-3 of October, 2025**

# Corporate Summary



GeneFrontier


***Founded:*** ***Oct 13<sup>th</sup>, 2010 (renewed)***

***Shareholder:*** ***KANEKA Corporation (100%)***


***People:*** ***17 (Ph.D. 8, MS 1)***

***Place:*** ***Chiba, Japan***



***Mission:*** ***Rebuilding and Manipulating Biological system  
for Inspiring the world!***



**Only necessary molecules  
for transcription/translation**




**=Breaking down & Building up**



## PURE system

*(Protein synthesis Using Recombinant Elements)*

***Shimizu Y. et al. Nature Biotechnology  
vol 19, p751–755 (2001)***




PURE system




*Reconstituted cell-free protein synthesis kit*



**PUREfrex<sup>®</sup>**

**For Designing Central Dogma**








**FASTIA: Fast Interaction Analysis**



Reconstituted cell-free protein synthesis kit

**PUREfres**

For Designing Central Dogma



Fujita et al. (2023) ACS Nano. vol.17(4), p.3358.





Sugii et al. (2023) Synth. Biol. vol.8, p1

et al. (2024) ACS Sens, 9(6):2846-2857.

Tsuboyama et al. (2023) Nature, 620, p434.



# -Improve Validation from Weeks to Days-

## FASTIA: Fast Interaction Analysis







[Matsunaga et al. \(2025\) Protein Sci. Mar;34\(3\):e70065. doi: 10.1002/pro.70065.](https://doi.org/10.1002/pro.70065)

## -Expression of scFv, Fab, IgG and more-




### Activity



[Murakami et al. \(2019\) Sci. Rep. vol.9, p.671. \(Supplementary Information\)](#)

[Murakami et al. \(2019\) Sci. Rep. vol.9, p.671.](#)



### Round 1: IFN-α variants tested by in vitro transcription/translation

HEK293 Human IFN $\alpha$ -Reporter Cells

Mouse B16 Reporter Cells

- Universal IFN- $\alpha$
- hIFN $\alpha$ \_L152F
- R121K
- R121K\_Q125R
- R121K\_Q125R\_K132T
- Y86C\_R121K\_Q125R
- Y86C\_R121K\_Q125R\_K132T
- mIFN2
- IFN $\alpha$ 2b
- scFv control
- Human IFN $\alpha$ 2b (starts at 1nM)
- No DNA

IFN- $\alpha$  variants were generated as IFN $\alpha$ -scFv fusions to identify mutations affecting activity in mouse and human cells


Anti-PDL1 scFv

IFN $\alpha$  VS Tag

IFN $\alpha$ -scFv protein was generated with an anti-PDL1 antibody by in vitro transcription/translation using the PUREfres<sup>®</sup> system (CosmoBIO USA). Protein mixture was serially diluted and protein was captured via an anti-V5 tag coated to the wells of the plate. Proteins were assayed for PD-L1 binding to assess expression (data not shown) or the ability to stimulate an IFN- $\alpha$  response in receptor reporter cell lines


[Killebrew et al. \(2024\) SITC 2024 Annual Meeting \(Poster, BONUMTX.com\).](#)

## -Application for complex molecule-



	1	2	3	4	5	6	7	8	9	10
	Proinsulin Aspart	Proinsulin Lispro	Proinsulin Glargine	Regular Proinsulin	Insulin A Chain	Insulin B Chain	Insulin A Chain Heterodimer	Insulin B Chain Heterodimer	Oxytocin	Glucagon
PURE	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Clm24	✗	✗	✗	✗	✓	✗	✓	✓	✓	✓
BL21	✗	✗	✗	✗	✓	✗	✓	✓	✓	✗
759	✓	✓	✓	✓	✓	✓	✓	✓	✓	✗
	11	12	13	14	15	16	17	18	19	20
	Glucagon Like Peptide 1 mutant (GLP-1 mut)	Glucagon Like Peptide 1 (GLP-1)	Insulin Like Growth Factor	Growth Hormone (GH)	Leptin	Vaso-pressin	Angiotensin II	Parathyroid Hormone (PTH)	Somato-statin	Leuprolide
PURE	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Clm24	✓	✓	✗	✓	✓	✓	✓	✓	✓	✓
BL21	✗	✗	✗	✗	✗	✗	✓	✓	✓	✓
759	✓	✓	✗	✓	✓	✓	✓	✗	✓	✓

[DeWinter et al. \(2023\) ACS Synth. Biol. vol.12, 4, p1216. \(Supplementary Information\)](#)




[Jensen et al. \(2021\) Protein Expr. Purif., 186, 105910.](#)






### In vitro expression and Biacore analysis of Fab fragments




### Kinetic analysis of 25 Fab binders



→ Selection of Fabs for further kinetic analysis


### EME Epsilon Molecular Engineering Molecular Design for Human Life



<https://www.epsilon-mol.co.jp/eng/>



### iBody's Ecobody Technology




Ecobody is...  
 • Human/Rabbit derived  
 • mAb in "Only 2" days!  
 • Fully in vitro screening  
 • No culture

<https://www.ibody.co.jp/en/>



### FUJIFILM peptide discovery services collaborated with PUREfres

- ✓ **Innovative improvements** in mRNA display enable screening from >10<sup>13</sup> peptides
- ✓ **Practical biosynthesis & assays** enable rapid selection and activity explorations.  
 → Peptides hits with **wide varieties** and **high-affinities** can be obtained.

We provide a CRO service, in which we receive target (🧬) from the customer\* and return the structural information of the acquired peptides (📄).  
\* Required target protein: 0.1~0.5 mg, >90% in purity




## -Broad applications, yet to come!-




Zimmermann I. et al. (2018) eLife, 7, e34317.

Wong et al. (2024) bioRxiv <https://doi.org/10.1101/2024.03.25.586624>.

### WET LAB EXPERIMENT: cell-free production and activity test of AMPs (24 hr)




Pandi et al. (2023) Nat Communications. vol.14(7197).



Jia B. et al. (2024) J Biosci Bioeng, 137(4):321-328.


## -Broad applications, yet to come!-



[Chui Z. et al. \(2024\) ACS Sens, 9\(6\):2846-2857.](#)

in vitro protein selection technology

# PUREfres<sup>®</sup> RD




Licensed technology under JP4931135 etc.

### ◆ Advanced screening system for Biologics



- **mAb (scFv / Fab)**
- **VHH**
- **Cyclic peptide**

### ◆ High Selection Efficiency

- **Completely molecular based system**
- **>10<sup>12</sup> diversity**




[Tsuboyama et al. \(2023\) Nature, 620, p434.](#)






Licensed to  
**SUTRO**  
BIOPHARMA



# -Broad applications, yet to come!-



[Pandi A et al. \(2022\) Nature Communications, 13, 3876.](#)



- ✓ Perfect fit to AI/ML approach with great controllability & reproducibility.
- ✓ Unique expression platform will give you great advantage in R&D.



## -KSF; AT rich codon on N-term-

### Fab Heavy Chain (Herceptin)

Herceptin Fab HC


Met- **Glu-Val-Gln-Leu-Val-** FLAG

2		3		4		5		6	
Glu		Val		Gln		Leu		Val	
codon	freq (%)	codon	freq (%)	codon	freq (%)	codon	freq (%)	codon	freq (%)
gaa	70	gtt	25	caa	30	ttg	15	gtt	25
gag	30	gtc	18	cag	70	tta	12	gtc	18
		gta	17			ctt	12	gta	17
		gtg	40			ctc	10	gtg	40
						cta	5		
						ctg	46		

Frequency (Glu, Gln)	65%	50%	35%
Frequency (Val, Leu)	35%	25%	15%

All clones; 384  
Tested clones; 56

\*Frequency is calculated from Codon Usage Database in Kazusa DNA Res.Inst. (E. coli K-12 strain)



Design of DNA template is important.


Manual is Free to download from our Web site here.



### PD1

Organism: *Homo sapiens*  
Synthesized region: 36Thr-150Glu-(Hisx8)  
Length: 124 a.a.  
Molecular weight: 14,148 Da


N-term type	1	2(38)	3(37)	4(38)	5(39)	6(40)	GC(%) 1-6 a.a.
GC	atg	acc	ttc	toc	cog	gog	67%
Major	atg	acc	ttt	tct	cog	gog	56%
AT	atg	act	ttt	tca	cca	gct	39%



### PDL1

Organism: *Homo sapiens*  
Synthesized region: 18Ala-239Thr-(Hisx8)  
Length: 231 a.a.  
Molecular weight: 26,593 Da


N-term type	1	2(18)	3(19)	4(20)	5(21)	6(22)	GC(%) 1-6 a.a.
GC	atg	gog	ttc	acc	gtg	acc	61%
Major	atg	gog	ttt	acc	gtg	acc	56%
AT	atg	gct	ttt	act	gta	aca	33%



### Citrate Synthase

Organism: *Saccharomyces cerevisiae*  
Synthesized region: 38Ser-479Asn  
Length: 443 a.a.  
Molecular weight: 49,346 Da


N-term type	1	2(38)	3(39)	4(40)	5(41)	6(42)	GC(%) 1-6 a.a.
GC	atg	toc	toc	gog	toc	gag	67%
Major	atg	tct	tct	gog	tct	gaa	44%
AT	atg	tca	tca	gct	tca	gaa	39%



### PTGDS

Organism: *Homo sapiens*  
Synthesized region: 23Ala-190Gln  
Length: 169 a.a.  
Molecular weight: 18,829 Da


N-term type	1	2(23)	3(24)	4(25)	5(26)	6(27)	GC(%) 1-6 a.a.
GC	atg	gca	cog	gaa	gca	cag	61%
Major	atg	gog	cog	gaa	gog	cag	72%
AT	atg	gca	cct	gaa	gct	caa	50%



### GM-CSF

Organism: *Homo sapiens*  
Synthesized region: 18Ala-144Glu  
Length: 128 a.a.  
Molecular weight: 14,608 Da


N-term type	1	2(18)	3(19)	4(20)	5(21)	6(22)	GC(%) 1-6 a.a.
GC	atg	gog	cog	gog	cgc	toc	83%
Major	atg	gog	cog	gog	cgc	tct	78%
AT	atg	gca	cct	gct	aga	tca	50%



### His-α-Synuclein



Organism: *Homo sapiens*  
Synthesized region: (Hisx6)-(Gly-Ser)-2(10)Asp-140(148)Ala  
Length: 148 a.a.  
Molecular weight: 15,427 Da

Tag type	1	2	3	4	5	6	7	8	9	GC(%) 1-9 a.a.
GC	atg	ccc	ccc	ccc	ccc	ccc	ccc	ggg	tct	59%
AT	atg	cat	cat	cat	cat	cat	cat	ggt	tct	37%



## -KSF; Quality of DNA-

#	Construct	Size (bp)	Elegen's ENFINIA DNA	Supplier B	Supplier C
			Format	Format	Format
1	HisTEV-sfGFP(G4Y)-PPG-FLAG	978	Linear dsDNA	N/A	Linear dsDNA
2	HisTEV-PPG-sfGFP(G4Y)-FLAG	978	Linear dsDNA	N/A	Linear dsDNA
3	HisTEV-sfGFP(G4Y)-FLAG	888	Linear dsDNA	Linear dsDNA	Linear dsDNA
4	sfGFP(G4Y)-FLAG	840	Linear dsDNA	Linear dsDNA	Linear dsDNA



### Protein





Figure 1. Analysis of DNA synthesized by three vendors. DNA synthesized by Elegen (Supplier A), Supplier B, and Supplier C quantified using a Qubit Fluorometer (Thermo Fisher) and subjected to agarose gel electrophoresis.



To learn more about ENFINIA DNA, visit [elegenbio.com](http://elegenbio.com) or contact us at [info@elegenbio.com](mailto:info@elegenbio.com)

## Contact information




Reconstituted cell-free protein synthesis kit

**PUREfrefx<sup>®</sup>**

*For reagent use for expression / screening of biologics  
/designing central dogma*

<https://purefrefx.genefrontier.com/>



in vitro protein selection technology

**PUREfrefx<sup>®</sup>RD**

*For screening service / collaboration / technology transfer  
for generation of new biologics*

**Takashi Ebihara, Ph.D., COO, GeneFrontier**

**E-mail: [ebihara@genefrontier.com](mailto:ebihara@genefrontier.com)**



# GMP VHH Antibody Manufacturing

We offer a robust VHH production platform, developed through extensive testing of diverse VHH models under a wide range of conditions:

- **mono-, bi-, and tri-specific** formats
- Isoelectric points between **pI 5 and 9**
- Diverse **hydrophobicity** properties



**8** only Months

Starting from your research cell bank, we rapidly identify the optimal setup and process conditions to efficiently produce your VHH.

## VHH Platform



### Two expression platforms

- *P. pastoris* (*K. phaffii*)
- *E. coli*



### Fermentation

- High-cell density fed-batch
- Control of critical fermentation parameters
- Animal-free media



### Purification types

- Ion-Exchange
- Hydrophobic Interaction Chromatography (HIC)
- Mix mode
- Affinity



### Quality control & release

- GMP QC package
- Additional custom QC development available
- QP release



Quick to clinic



Designed for Tox & PhI



GMP quality



End-to-End assistance